Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening

Leigh M. Matano, Heidi G. Morris, B. Mc Kay Wood, Timothy Charles Meredith, Suzanne Walker

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Since the introduction of penicillin into the clinic in 1942, antibiotics have saved the lives of millions of people around the world. While penicillin and other traditional broad spectrum antibiotics were effective as monotherapies, the inexorable spread of antibiotic resistance has made alternative therapeutic approaches necessary. Compound combinations are increasingly seen as attractive options. Such combinations may include: lethal compounds; synthetically lethal compounds; or administering a lethal compound with a nonlethal compound that targets a virulence factor or a resistance factor. Regardless of the therapeutic strategy, high throughput screening is a key approach to discover potential leads. Unfortunately, the discovery of biologically active compounds that inhibit a desired pathway can be a very slow process, and an inordinate amount of time is often spent following up on compounds that do not have the desired biological activity. Here we describe a pathway-directed high throughput screening paradigm that combines the advantages of target-based and whole cell screens while minimizing the disadvantages. By exploiting this paradigm, it is possible to rapidly identify biologically active compounds that inhibit a pathway of interest. We describe some previous successful applications of this paradigm and report the discovery of a new class of D-alanylation inhibitors that may be useful as components of compound combinations to treat methicillin-resistant Staphylococcus aureus (MRSA).

Original languageEnglish (US)
Pages (from-to)6307-6314
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume24
Issue number24
DOIs
StatePublished - Jan 1 2016

Fingerprint

Penicillins
Screening
Anti-Bacterial Agents
R Factors
Virulence Factors
Methicillin-Resistant Staphylococcus aureus
Microbial Drug Resistance
Throughput
Methicillin
Bioactivity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Matano, Leigh M. ; Morris, Heidi G. ; Wood, B. Mc Kay ; Meredith, Timothy Charles ; Walker, Suzanne. / Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening. In: Bioorganic and Medicinal Chemistry. 2016 ; Vol. 24, No. 24. pp. 6307-6314.
@article{b3cccb6fdb3e48b0bdf376a868cc807f,
title = "Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening",
abstract = "Since the introduction of penicillin into the clinic in 1942, antibiotics have saved the lives of millions of people around the world. While penicillin and other traditional broad spectrum antibiotics were effective as monotherapies, the inexorable spread of antibiotic resistance has made alternative therapeutic approaches necessary. Compound combinations are increasingly seen as attractive options. Such combinations may include: lethal compounds; synthetically lethal compounds; or administering a lethal compound with a nonlethal compound that targets a virulence factor or a resistance factor. Regardless of the therapeutic strategy, high throughput screening is a key approach to discover potential leads. Unfortunately, the discovery of biologically active compounds that inhibit a desired pathway can be a very slow process, and an inordinate amount of time is often spent following up on compounds that do not have the desired biological activity. Here we describe a pathway-directed high throughput screening paradigm that combines the advantages of target-based and whole cell screens while minimizing the disadvantages. By exploiting this paradigm, it is possible to rapidly identify biologically active compounds that inhibit a pathway of interest. We describe some previous successful applications of this paradigm and report the discovery of a new class of D-alanylation inhibitors that may be useful as components of compound combinations to treat methicillin-resistant Staphylococcus aureus (MRSA).",
author = "Matano, {Leigh M.} and Morris, {Heidi G.} and Wood, {B. Mc Kay} and Meredith, {Timothy Charles} and Suzanne Walker",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.bmc.2016.08.003",
language = "English (US)",
volume = "24",
pages = "6307--6314",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "24",

}

Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening. / Matano, Leigh M.; Morris, Heidi G.; Wood, B. Mc Kay; Meredith, Timothy Charles; Walker, Suzanne.

In: Bioorganic and Medicinal Chemistry, Vol. 24, No. 24, 01.01.2016, p. 6307-6314.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening

AU - Matano, Leigh M.

AU - Morris, Heidi G.

AU - Wood, B. Mc Kay

AU - Meredith, Timothy Charles

AU - Walker, Suzanne

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Since the introduction of penicillin into the clinic in 1942, antibiotics have saved the lives of millions of people around the world. While penicillin and other traditional broad spectrum antibiotics were effective as monotherapies, the inexorable spread of antibiotic resistance has made alternative therapeutic approaches necessary. Compound combinations are increasingly seen as attractive options. Such combinations may include: lethal compounds; synthetically lethal compounds; or administering a lethal compound with a nonlethal compound that targets a virulence factor or a resistance factor. Regardless of the therapeutic strategy, high throughput screening is a key approach to discover potential leads. Unfortunately, the discovery of biologically active compounds that inhibit a desired pathway can be a very slow process, and an inordinate amount of time is often spent following up on compounds that do not have the desired biological activity. Here we describe a pathway-directed high throughput screening paradigm that combines the advantages of target-based and whole cell screens while minimizing the disadvantages. By exploiting this paradigm, it is possible to rapidly identify biologically active compounds that inhibit a pathway of interest. We describe some previous successful applications of this paradigm and report the discovery of a new class of D-alanylation inhibitors that may be useful as components of compound combinations to treat methicillin-resistant Staphylococcus aureus (MRSA).

AB - Since the introduction of penicillin into the clinic in 1942, antibiotics have saved the lives of millions of people around the world. While penicillin and other traditional broad spectrum antibiotics were effective as monotherapies, the inexorable spread of antibiotic resistance has made alternative therapeutic approaches necessary. Compound combinations are increasingly seen as attractive options. Such combinations may include: lethal compounds; synthetically lethal compounds; or administering a lethal compound with a nonlethal compound that targets a virulence factor or a resistance factor. Regardless of the therapeutic strategy, high throughput screening is a key approach to discover potential leads. Unfortunately, the discovery of biologically active compounds that inhibit a desired pathway can be a very slow process, and an inordinate amount of time is often spent following up on compounds that do not have the desired biological activity. Here we describe a pathway-directed high throughput screening paradigm that combines the advantages of target-based and whole cell screens while minimizing the disadvantages. By exploiting this paradigm, it is possible to rapidly identify biologically active compounds that inhibit a pathway of interest. We describe some previous successful applications of this paradigm and report the discovery of a new class of D-alanylation inhibitors that may be useful as components of compound combinations to treat methicillin-resistant Staphylococcus aureus (MRSA).

UR - http://www.scopus.com/inward/record.url?scp=84994068274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994068274&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2016.08.003

DO - 10.1016/j.bmc.2016.08.003

M3 - Article

C2 - 27594549

AN - SCOPUS:84994068274

VL - 24

SP - 6307

EP - 6314

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 24

ER -